These analyses provide complementary information from the same tissue samples. Histopathology examines structural and cellular features under a microscope, while molecular testing evaluates tissue-level signals that may help characterize disease. Using both approaches can reveal abnormalities that are not evident from imaging or blood tests, strengthening diagnostic assessment when clinicians suspect myocarditis, infiltrative disease, storage disorders, or unexplained cardiomyopathy.
The catheter-based procedure collects several small heart-muscle fragments rather than relying on a single specimen. These fragments can support microscopic examination and specialized molecular testing, allowing the laboratory to assess the sampled tissue through more than one analytical approach. The resulting findings may help clinicians identify disease, evaluate activity, and make treatment or monitoring decisions.
Imaging and blood tests provide indirect information about cardiac structure, function, or circulating indicators. A myocardial biopsy provides tissue for direct microscopic and molecular examination. That direct assessment can identify abnormalities within heart muscle when other evaluations do not clearly explain the clinical picture, which is particularly relevant in suspected myocarditis, infiltrative or storage disorders, and unexplained cardiomyopathy.
Clinicians use this procedure when they suspect myocarditis, infiltrative disease, storage disorders, or an otherwise unexplained cardiomyopathy. It also has an important role after heart transplantation, where tissue findings can detect rejection. In these settings, biopsy results add diagnostic or surveillance information that can support treatment decisions and help assess whether disease or transplant-related injury remains active.
A catheter is guided through a blood vessel toward the heart, commonly into the right ventricle. Biopsy forceps passed through the catheter remove several small fragments of heart muscle. The specimens then undergo histopathology and, when indicated, specialized molecular testing. Clinicians interpret these results alongside the broader clinical evaluation to identify disease or monitor a known condition.
After transplantation, clinicians use myocardial biopsy to look for tissue evidence of rejection. The procedure can therefore provide direct diagnostic information during post-transplant evaluation and ongoing clinical monitoring. Its findings may help determine whether transplant-related injury is present and support decisions about treatment or follow-up, rather than relying only on indirect clinical information.